Nomura Phase4 Ventures Limited
1 Angel Lane, London, England, EC4R 3AB, United Kingdom
Overview
Phase4 Ventures is a venture capital firm based in London that invests in development stage life science companies in the US and Europe. Founded in 1999, the team has made close to 30 investments in Life Science companies alongside other top tier venture capital firms in both Europe and the US. The team is complemented by an extensive group of advisors with operating experience at a senior level in pharmaceutical and biotechnology companies. Phase4 Ventures' investments include many of the companies that have provided successful European and US venture exits including Intercell, Pharmion, Targacept and most recently Proteolix. Phase4 Ventures was spun-out from Nomura in December 2010 following a buy out of the management company by the team and a secondary purchase of a fund by HarbourVest Partners. Phase4 Ventures currently manages funds for both Nomura and HarbourVest. Phase4 Ventures Limited is a member of the British Private Equity and Venture Capital Association (BVCA) and the European Private Equity and Venture Capital Association (EVCA).
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- Nabriva Therapeutics
Participated · Equity · Oct 2009
Nabriva Therapeutics AG is a Vienna- and Philadelphia-based biotechnology company focused on the discovery and development of pleuromutilin antibiotics. Its lead product, lefamulin (BC‑3781), is the first systemically available pleuromutilin for human use and is entering pivotal phase 3 studies for community-acquired bacterial pneumonia (CABP). Lefamulin shows in vitro activity against the most common CABP pathogens, including S. pneumoniae, H. influenzae, M. catarrhalis, S. aureus, M. pneumoniae, L. pneumophila and C. pneumoniae, including multi-drug resistant strains. Preclinical programs include Extended Spectrum Pleuromutilins (ESPs), a new generation targeting CDC‑identified urgent and serious threats such as carbapenem-resistant Enterobacteriaceae (CRE). The company is led by CEO Dr Colin Broom. Nabriva completed a $120M Series B financing, with an initial $50M tranche to advance lefamulin into phase 3 studies and to continue pipeline development. Nabriva Therapeutics is a Vienna, Austria–based biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens. Its core program is a systemic pleuromutilin antibiotic program. The company plans to use funds to advance that program up to and including the generation of phase II efficacy data in the second half of 2010. Nabriva closed a €15M equity financing from existing investors to support development. The financing extends the company's cash reach into 2011, according to CEO Dr. David Chiswell. Since its foundation in 2006 the company has raised €57.4M (approximately $84M) in total equity funding.
Team
No current team members are available.